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Cross-Reactivity of Three 
Recombinant Insulin Analogs with 
Five Commercial Insulin 
Immunoassays
To the Editor:
Several new  insulin analogs that are 
prepared w ith recom binant D N A  
tech nology  are available for clinical 
use [for a recent review , see Ref. ( 1 )]. 
These agents have altered pharm a­
cokinetics com pared  w ith regular 
hum an insulin. Insulin a sp a rt(N o v o - 
L o g 1M; N o v o  N ord isk  Pharm aceuti­
cals) is h o m o lo g o u s  w ith regular h u ­
man insulin except for a single 
substitution o f  aspartic acid for p ro ­
line at position  B28. This single su b ­
stitution reduces the m olecu le 's  ten­
den cy  to form  hexam ers. Therefore, 
insulin aspart is absorbed m ore rap­
id ly  after su bcutaneous injection and 
has both  a faster onset o f  action and a 
shorter duration  o f  action than regu ­
lar insulin. A second  short-acting re­
com binant insulin is insulin lispro 
(H um alog® ; Eli Lilly and C om p an y), 
w hich  is a hum an insulin analog
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created by  reversing the am in o acids 
at p osition s 28 (Pro to Lys) and 29 
(Lys to Pro) o f  the B chain. It is 
absorbed m ore  rapid ly  than regular 
hum an insulin w hen  adm inistered 
subcutaneously  and has a shorter d u ­
ration o f  action.
A third recom binant insulin that is 
lon ger acting is insulin glargine 
(Lantus®; A ventis Pharm aceuticals), 
w hich  d iffers from  regular hum an 
insulin by  the substitution o f g lycin e 
for asparagine at position  A21 and 
by  the addition  o f tw o  arginine resi­
dues to the C O O H  term inus o f  the B 
chain. These m od ifications lead to a 
slow er, m ore  p ro lon ged  absorption  
than regular insulin and a relatively 
stable concentration -tim e profile  
over 24 h. Insulin glargine is partially 
m etabolized at the C O O H  term inus 
o f the B chain in the subcutaneous 
dep ot to form  tw o  active m etabolites, 
M l and M 2, w ith in v itro  activity 
sim ilar to that o f  insulin. M etabolite 
M l is 21A-G ly-insu lin , and m etabo­
lite M 2 is 21A-G ly-d es-30B-Thr-insu- 
lin.
O ne ob v iou s  question  w ith these 
recom binant preparations is w hether 
they are detectable by  im m unoassay. 
Im m unoassays have been deve lop ed  
specifica lly  for pharm acokinetic 
studies o f  insulin analogs. A sensi­
tive RIA that is specific  for insulin 
lispro and an ELISA that is specific 
for insulin aspart have been d eve l­
oped  (2 ,3 ) .  A chem ilum inescent en ­
zy m e  im m unoassay that can qu an ­
tify hum an insulin , proinsulin , 
despentapeptide insulin, porcin e  in­
sulin, and insulin lispro w ith com p a ­
rable cross-reactivity has also been 
described (4).  T w o  insulin assays, 
on e that can specifically  quantify  h u ­
man insulin and a second  w ith  w hich  
hum an insulin, insulin aspart, and 
insulin lispro cross-react equally, 
have been used to estimate the co n ­
centration o f insulin aspart or lispro 
by  subtraction ( 5 ). A ll o f  these assays 
are used prim arily  for research and 
are not com m on ly  used in clinical 
laboratories. T w o  reports have ap ­
peared in this journal describ ing  the 
use o f  a com m ercia l RIA for quanti­
fy ing  insulin lispro ( 6 , 7) .  O nly  one 
study to date has exam ined the cross­
reactivity o f  insulin lispro w ith an
autom ated insulin assay on a m u l­
tichannel, random -access analyzer 
(8).  These authors found that the 
cross-reactivity o f  insulin lispro in 
the Elecsys insulin assay w as 
< 0.02% . The g oa l o f  this study w as 
to quantify  the cross-reactivity o f  in­
sulin aspart, insulin glargine, and 
insulin lispro w ith  several com m er­
cial insulin assays to determ ine 
w hich  m ight be  sp ecific  for hum an 
insulin and w hich  m ight sh ow  cross­
reactivity w ith the insulin analogs. 
Four o f the five  insulin assays w ere 
perform ed on autom ated, m ultichan­
nel, ran dom -access analyzers that are 
available in clinical laboratories.
W e obtained vials o f  each o f the 
three insulin analogs, w ith  a nom inal 
concentration  o f  100 lU /m L a n d  suit­
able for in jection, from  ou r hospital 
pharm acy. Each w as diluted v o lu - 
m etrically w ith 60 g /L  aqu eou s b o ­
v ine serum  album in to final insulin 
concentrations o f  30, 100, 300, and 
1000 m lU /L . A ll d ilutions o f  each 
insulin preparation  w ere  analyzed in 
duplicate, and the percentage cross­
reactivity w as calculated from  the 
ratio o f  the m easured and nom inal 
concentration. M easurem ents w ere 
m ade on an A ccess analyzer (Beck­
man C oulter), an A dvia  Centaur an­
alyzer (Bayer D iagnostics), an E170
Analog and concentration Access Advia Centaur
Insulin aspart
30 mlU/L 85.3 1 2 0
100 mlU/L 80.0 124
300 mlU/L 84.3 135
1000 mlU/L 77.1 125
Mean 81.7 126
Insulin glargine
30 mlU/L 91.7 129
100 mlU/L 85.0 140
300 mlU/L 78.7 152
1000 mlU/L 79.7 150
Mean 83.8 143
Insulin lispro
30 mlU/L 78.7 86.7
100 mlU/L 77.0 89.0
300 mlU/L 79.3 92.3
1000 mlU/L 80.2 89.2
Mean 78.8 89.3
analyzer (R oche D iagnostics), and an 
IM M ULITE 2000 analyzer (D iagn os­
tics P roducts C orporation ), using the 
m anufacturers' reagents accord ing  
to the instructions. T w o  lots o f  re­
agent for the IM MULITE 2000 w ere 
exam ined: lot 122, w hich  is the old 
form ulation , and lot 151, w hich  is a 
new  form ulation , presum ably  w ith  a 
change in on e or both  antibodies. In 
ad d ition , a m anual assay, C oat-A - 
C ou n t (D iagnostic P roducts C o rp o ­
ration), w as also used for testing.
A sum m ary o f the recoveries o b ­
served for each com bination  o f  ana­
lo g  and assay m ethod is presented in 
Table 1. A ll analogs had an equ iva ­
lent cross-reactivity o f  80%  w ith the 
A ccess m ethod . This m ay represent 
cross-reactivity that is truly <100% , 
or assay calibration m ay not exactly 
match the nom inal concentration  o f 
each insulin analog. Insulin lispro 
dem onstrated 90%  cross-reactivity 
on the A dv ia  Centaur, w hereas insu­
lin aspart and glargine had mean 
cross-reactivities o f  126% and 143%, 
respectively. Each o f the analogs 
had 3 5 -4 5 %  cross-reactivity w ith 
the C oa t-A -C ou n t assay. The E170 
m ethod did  not detect any o f  the 
three analogs even at the h ighest 
concentrations tested. Both insulin 
aspart and lispro had —28%  cross-
Coat-A-Count E170 Lot 122 Lot 151
36.7 <0.7 14.7 9.3
57.0 <0.2 17.4 5.4
54.7 <0.07 40.7 8 .0
34.4 <0.02 40.7 13.0
45.7 28.4 8.9
32.0 <0.7 <6.7 8.3
46.0 <0.2 3.4 2 .8
35.7 <0.07 1 1 .1 1 .6
27.1 <0.02 13.2 1 .8
35.2 9.2 3.6
37.0 <0.7 14.7 10.3
52.0 <0.2 18.0 6.3
49.7 <0.07 42.3 8.4
33.4 <0.02 39.3 12.3
43.0 28.6 9.3
Table 1. Cross-reactivities of insulin analogs.
Cross-reaetlvlty, %
IMMULITE 2000
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reactivity w ith the o ld  form ulation  
assay on the FMMULFTE 2000, and 
insulin glargine had 9%  cross-reac­
tivity. Both insulin aspart and lispro 
had 9%  cross-reactivity w ith  the new  
form ulation  assay on the FMMULFTE 
2000, and insulin g largine had —4%  
cross-reactivity.
The large variability in insulin an­
a log  cross-reactivities w ith different 
com m ercial assays is notew orthy. 
The least cross-reactivity w as o b ­
served for the E170 m ethod , w hich  
had a cross-reactivity o f  < 0 .02 %  for 
all three analogs. O ur result o f  no 
detectable cross-reactivity for insulin 
lispro is in agreem ent w ith  a p rev i­
ou s report (8).  This suggests that one 
an tibody  used in this assay recog ­
nizes either an ep itop e  that includes 
A21 or an ep itope  that includes B28 
and the C O O H  term inus o f  the B 
chain. Substitutions at on e o f these 
position s abolish  im m unoreactivity.
The A ccess assay dem onstrated 
sim ilar recoveries for all three ana­
logs that w ere  c lose  to the nom inal 
concentrations. Ft seem s plausible 
that neither an tibody  used in this 
assay recogn izes an ep itop e  close  to 
A21 or B 2 8 /C O O H  term inus because 
neither substitution affected insulin 
recovery. The h ighest cross-reactivity 
w as for insulin glargine on the A d v ia  
Centaur, w ith  152% cross-reactivity 
at 300 m FU /L. This m ethod also 
sh ow ed  a cross-reactivity o f  126% for 
insulin aspart. The substitutions at 
A21 and B28 enhance the b in d in g  o f 
the antibodies used in this assay. The 
C oat-a -C oun t and FMMULFTE 2000 
insulin assays, w hich  are from  the 
sam e m anufacturer, apparently use 
d ifferent antibodies. The reform ula­
tion o f  the FMMULFTE 2000 assay led
to a decreased cross-reactivity w ith 
all three analogs.
Ft is also interesting that the cross­
reactivity can be  concentration  d e ­
pendent. This w as m ost notable for 
the FMMULFTE 2000 assay. F’ reviou s 
studies o f  the C oat-a -C oun t assay 
w ith insulin lispro fou nd  a cross­
reactivity o f  —100% w ith on e lot o f 
RFA tubes and a cross-reactivity o f 
186% w ith a d ifferent lot (7).  W e 
fou nd  a mean cross-reactivity o f  43% , 
suggesting  that there m ay have been 
another change in the antibodies 
used com pared  w ith  earlier studies.
Ft m ay be  im portant for clinicians 
to b e  aw are o f the cross-reactivities 
o f  various insulin analogs w ith the 
assay(s) used b y  an individual clini­
cal laboratory. U nfortunately, the 
package inserts for the assays w e  
evaluated did  not in clude this in for­
m ation. A n  update to the package 
insert about cross-reactivity w ith in­
sulin analogs w ou ld  also b e  desirable 
if an assay is m od ified , particularly if 
an an tibody  w ere  changed. A nother 
interesting p o in t from  this study is 
that a com bination  o f com m ercial 
assays can be  used to estim ate the 
concentrations o f  these insulin ana­
logs in the presence o f  hum an insu­
lin. For exam ple, the E170 m easures 
on ly  hum an insulin, w hereas the A c ­
cess insulin assay m easures all three 
analogs w ith a cross-reactivity o f 
—80%. Use o f a com bination  o f  these 
tw o  assays shou ld  m ake it p ossib le  to 
estim ate the concentration  o f any o f 
these three insulin analogs in the 
presence o f  hum an insulin.
The ARUF’  Fnstitute for Clinical and 
Experim ental F’ a th ology  p rov id ed  
su p p ort for this study.
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